SMC-话题@MedSci

#SMC#

10篇内容 | 1210人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2249653, encodeId=6de5224965341, content=<a href='/topic/show?id=37b083e182b' target=_blank style='color:#2F92EE;'>#胚胎干细胞#</a> <a href='/topic/show?id=251e10183059' target=_blank style='color:#2F92EE;'>#骨肉瘤#</a> <a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=2025年1月Cell期刊精华, objectType=article, longId=861014, objectId=02c2861014d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250125/1737768397323_2185383.png, objectUrl=/article/show_article.do?id=02c2861014d1, replyNumber=0, likeNumber=7, createdTime=2025-01-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1937877, encodeId=7b49193e87746, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, objectType=article, longId=218568, objectId=c15d218568ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d218568ba, replyNumber=0, likeNumber=111, createdTime=2022-06-08, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d218568ba, moduleTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15d218568ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937879, encodeId=5788193e879a2, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）, objectType=article, longId=292253, objectId=112d2922537c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112d2922537c, replyNumber=0, likeNumber=81, createdTime=2022-11-22, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112d2922537c, moduleTitle=SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112d2922537c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937878, encodeId=7ceb193e87815, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, objectType=article, longId=220349, objectId=a6392203493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6392203493e, replyNumber=0, likeNumber=67, createdTime=2022-08-01, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6392203493e, moduleTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6392203493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937876, encodeId=9a82193e876af, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=Lancet：季节性疟疾化学预防计划（SMC）实施效果评估, objectType=article, longId=204212, objectId=b5fd20421222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5fd20421222, replyNumber=0, likeNumber=72, createdTime=2021-05-15, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5fd20421222, moduleTitle=Lancet：季节性疟疾化学预防计划（SMC）实施效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5fd20421222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937875, encodeId=a57c193e8751a, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, objectType=article, longId=166117, objectId=2c7916611e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7916611e50, replyNumber=0, likeNumber=89, createdTime=2019-08-01, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7916611e50, moduleTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7916611e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937874, encodeId=aa81193e8744e, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=Sci Rep：晚期糖基化终产物通过HIF-1α/PDK4活化加速VSMC中的钙化并抑制葡萄糖代谢, objectType=article, longId=149234, objectId=de5f14923467, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de5f14923467, replyNumber=0, likeNumber=82, createdTime=2018-10-21, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de5f14923467, moduleTitle=Sci Rep：晚期糖基化终产物通过HIF-1α/PDK4活化加速VSMC中的钙化并抑制葡萄糖代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de5f14923467)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937873, encodeId=54e8193e87342, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=SMC批准Xermelo进行类癌综合征腹泻, objectType=article, longId=141555, objectId=c6fc141555d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6fc141555d9, replyNumber=0, likeNumber=92, createdTime=2018-08-19, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6fc141555d9, moduleTitle=SMC批准Xermelo进行类癌综合征腹泻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6fc141555d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937872, encodeId=f562193e87220, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=J Cell Physiol：高糖处理的牙龈卟啉单胞菌在人主动脉SMCs钙化中的作用, objectType=article, longId=120844, objectId=1da1120844a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da1120844a7, replyNumber=0, likeNumber=61, createdTime=2018-02-05, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da1120844a7, moduleTitle=J Cell Physiol：高糖处理的牙龈卟啉单胞菌在人主动脉SMCs钙化中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da1120844a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937871, encodeId=57d7193e87104, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, objectType=article, longId=82087, objectId=8c028208e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c028208e2d, replyNumber=0, likeNumber=89, createdTime=2017-06-30, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c028208e2d, moduleTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c028208e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937870, encodeId=6de8193e870c4, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, objectTitle=Exp Lung Res：肺动脉ERK表达或与吸烟者PASMC的异常增殖相关, objectType=article, longId=20383, objectId=66412038333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66412038333, replyNumber=0, likeNumber=91, createdTime=2013-09-21, rootId=0, userName=huhuaidong387, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66412038333, moduleTitle=Exp Lung Res：肺动脉ERK表达或与吸烟者PASMC的异常增殖相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66412038333)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SMC

2020-05-29

梅斯管理员

前往app查看评论内容

2025-01-26发表于上海

huhuaidong387

#SMC#

苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者

2022-06-08

huhuaidong387

#SMC#

SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）

2022-11-22

huhuaidong387

#SMC#

苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）

2022-08-01

huhuaidong387

#SMC#

Lancet：季节性疟疾化学预防计划（SMC）实施效果评估

2021-05-15

huhuaidong387

#SMC#

苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌

2019-08-01

huhuaidong387

#SMC#

Sci Rep：晚期糖基化终产物通过HIF-1α/PDK4活化加速VSMC中的钙化并抑制葡萄糖代谢

2018-10-21

huhuaidong387

#SMC#

SMC批准Xermelo进行类癌综合征腹泻

2018-08-19

huhuaidong387

#SMC#

J Cell Physiol：高糖处理的牙龈卟啉单胞菌在人主动脉SMCs钙化中的作用

2018-02-05

huhuaidong387

#SMC#

瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗

2017-06-30

huhuaidong387

#SMC#

Exp Lung Res：肺动脉ERK表达或与吸烟者PASMC的异常增殖相关

2013-09-21